The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.
• ONE (or more) First Order Criterion:
∙ Known inherited thrombophilia diagnosed prior to enrolment, regardless of family history of VTE:
∙ i. Heterozygous factor V Leiden, or ii. Heterozygous prothrombin gene variant, or iii. Protein C deficiency, or iv. Protein S deficiency, and/or
‣ Antepartum immobilization for ≥7 days. Immobilization is defined as bed rest with 90% of waking hours spent in bed at any time during the antepartum period AND/OR
• TWO (or more) Second Order Criteria:
⁃ Pre-pregnancy BMI ≥30 kg/m²
⁃ Smoking in the current pregnancy or within 3 months prior to pregnancy
⁃ Previous clinical history of superficial vein thrombosis
⁃ Preeclampsia
⁃ Current pregnancy ending in stillbirth (pregnancy loss \>20 weeks gestation)
⁃ Unplanned cesarean delivery (unplanned = not a scheduled cesarean delivery)
⁃ Small-for-gestational-age infant at time of delivery (\<3rd percentile adjusted for gestational age and sex)
⁃ Peripartum or postpartum infection (symptoms/signs of infection and documented fever and laboratory evidence of infection with positive blood cultures or an elevated white blood cell count based on local laboratory cutoffs)
⁃ Postpartum hemorrhage (≥1000 mL of blood loss, regardless of delivery mode)